ArticleNuclear medicine and molecular imaging2015
Imaging Findings and Literature Review of (18)F-FDG PET/CT in Primary Systemic AL Amyloidosis.
Article in Nuclear medicine and molecular imaging, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Cardiac amyloidosis: From diagnosis to therapeutics breakthroughs.World journal of experimental medicine · 2026Review
- Cardiac magnetic resonance imaging and cardiac scintigraphy in the diagnosis of cardiac amyloidosis: A meta-analysis of 4866 patients.Journal of molecular and cellular cardiology plus · 2025Article
- An incidental pulmonary amyloidoma detected duringRadiology case reports · 2025Article
- A New Era for PET/CT: Applications in Non-Tumorous Renal Pathologies.Journal of clinical medicine · 2024Review
- Nodular pulmonary amyloidosis diagnosed by ultrasound-guided percutaneous needle biopsy.Respiratory medicine case reports · 2024Article
- Diffuse 18F-FDG PET Uptake in a Patient With Biopsy-Proven ATTR Cardiac Amyloidosis: A Potential Pitfall in Interpretation.CJC open · 2023Article
- Multimodality Imaging in the Diagnosis and Assessment of Cardiac Amyloidosis.World journal of nuclear medicine · 2022Review
- New Advanced Imaging Parameters and Biomarkers-A Step Forward in the Diagnosis and Prognosis of TTR Cardiomyopathy.Journal of clinical medicine · 2022Review
- FDG avid pulmonary amyloid nodule in a patient with metastatic renal cell cancer on 18F-FDG PET/CT.Radiology case reports · 2022Article
- Series of myocardial FDG uptake requiring considerations of myocardial abnormalities in FDG-PET/CT.Japanese journal of radiology · 2021Review
- Nuclear Imaging for the Diagnosis of Cardiac Amyloidosis in 2021.Diagnostics (Basel, Switzerland) · 2021Review
- Procedural recommendations of cardiac PET/CT imaging: standardization in inflammatory-, infective-, infiltrative-, and innervation (4Is)-related cardiovascular diseases: a joint collaboration of the EACVI and the EANM.European journal of nuclear medicine and molecular imaging · 2021Article
- Procedural recommendations of cardiac PET/CT imaging: standardization in inflammatory-, infective-, infiltrative-, and innervation- (4Is) related cardiovascular diseases: a joint collaboration of the EACVI and the EANM: summary.European heart journal. Cardiovascular Imaging · 2020Article
- Performance ofJournal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2020Article
- Multimodality Imaging in the Evaluation and Management of Cardiac Amyloidosis.Seminars in nuclear medicine · 2020Review
- Quantitative [European journal of nuclear medicine and molecular imaging · 2020Article
- Mesenteric Amyloidosis: Radiologic Imaging with Pathologic Correlation.Journal of clinical imaging science · 2020Article
- The Role of Multi-modality Imaging in the Diagnosis of Cardiac Amyloidosis: A Focused Update.Frontiers in cardiovascular medicine · 2020Review
- Molecular Imaging of Cardiac Amyloidosis.Current cardiology reports · 2019Review
- Imaging of Myocardial Ischemia-Reperfusion Injury Using Sodium [Molecular imaging · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeAlthough several case reports and case series have described (18)F-FDG PET/CT in amyloidosis, the value of (18)F-FDG PET/CT for diagnosing amyloidosis has not been clarified. We investigated the imaging findings of (18)F-FDG PET/CT in patients with primary systemic AL amyloidosis.
methodsSubjects were 15 patients (M:F = 12:3; age, 61.5 ± 7.4 years) with histologically confirmed primary systemic AL amyloidosis who underwent pretreatment (18)F-FDG PET/CT to rule out the possibility of malignancy or for initial workup of alleged cancer. For involved organs, visual and semiquantitative analyses were performed on (18)F-FDG PET/CT images. In total, 22 organs (10 hearts, 5 kidneys, 2 stomachs, 2 colons, 1 ileum, 1 pancreas, and 1 liver) were histologically confirmed to have primary systemic AL amyloidosis.
resultsF-FDG uptake was significantly increased in 15 of the 22 organs (68.2 %; 10 hearts, 2 kidneys, 1 colon, 1 ileum, and 1 liver; SUVmax = 7.0 ± 3.2, range 2.1-14.1). However, in 11 of 15 PET-positive organs (78.6 %; 10 hearts and the ileum), it was difficult to differentiate pathological uptake from physiological uptake. Definitely abnormal (18)F-FDG uptake was found in only 4 of the 22 organs (18.2 %; 2 kidneys, 1 colon, and the liver). (18)F-FDG uptake was negative for pancreas and gastric lesions.
conclusionsAlthough (18)F-FDG PET/CT showed high uptake in two-thirds of the organs involving primary systemic AL amyloidosis, its sensitivity appeared to be low to make differentiation of pathological uptake from physiological uptake. However, due to the small number of cases, further study for the role of (18)F-FDG PET/CT in amyloidosis will be warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.